# Clinical Trials Data EGFR - Document 108

# Studying Tumor Tissue Samples and Blood Samples to Learn More About DNA Changes in Patients With Lung Cancer

## Clinical Trial: https://clinicaltrials.gov/study/NCT00899405

"eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n\* Histologically or cytologically confirmed lung cancer\n\nPATIENT CHARACTERISTICS:\n\n\* Not specified\n\nPRIOR CONCURRENT THERAPY:\n\n\* May have received prior EGFR inhibitors",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Patients with lung cancer",

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided clinical trial information, a patient with an EGFR gene mutation appears to be eligible for the clinical trial. The eligibility criteria mention that the trial is for patients with histologically or cytologically confirmed lung cancer, and it does not specifically exclude patients with an EGFR gene mutation. Additionally, the criteria allow for patients who may have received prior EGFR inhibitors, which suggests that having an EGFR mutation does not disqualify them from participating. Furthermore, the trial is open to all sexes, requires participants to be 18 years or older, and does not involve healthy volunteers, focusing specifically on patients with lung cancer.